Filter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Eisai Initiates BLA Submission of Data for Lecanemab in China
December 22, 2022 - … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and …
Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
December 19, 2022 - … Genentech; the potential of our commercial business and pipeline programs and risks and uncertainties associated with … Genentech; the potential of our commercial business and pipeline programs and risks and uncertainties associated with … Genentech; the potential of our commercial business and pipeline programs and risks and uncertainties associated with …
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
December 9, 2022 - … the potential of Biogen’s commercial business and pipeline programs; Biogen’s strategy and plans; and potential … the potential of Biogen’s commercial business and pipeline programs; Biogen’s strategy and plans; and potential … the potential of Biogen’s commercial business and pipeline programs; Biogen’s strategy and plans; and potential …
Eleven Experts From Leading Medical Institutions And Eight Experts From Eisai* Publish Full Results Of Lecanemab Phase 3 Confirmatory Clarity Ad Study For Early Alzheimer’s Disease In The New England Journal Of Medicine
November 29, 2022 - … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and …
Biogen and Sage Therapeutics Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
December 6, 2022 - … and PPD; the potential of Biogen’s commercial business and pipeline programs, including zuranolone; the anticipated … and PPD; the potential of Biogen’s commercial business and pipeline programs, including zuranolone; the anticipated … and PPD; the potential of Biogen’s commercial business and pipeline programs, including zuranolone; the anticipated …
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease At Clinical Trials On Alzheimer’s Disease (Ctad) Conference
November 29, 2022 - … Eisai ; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … Eisai ; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … Eisai ; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and …
European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS
December 5, 2022 - … sensitive clinical endpoints. Today, the company has a pipeline of investigational drugs being evaluated in ALS, … of ALS; the potential of our commercial business and pipeline programs, including tofersen; and risks and … sensitive clinical endpoints. Today, the company has a pipeline of investigational drugs being evaluated in ALS, …
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
November 22, 2022 - … on advancing one of the industry’s most diversified pipeline in neuroscience that will transform the standard of … and PPD; the potential of Biogen’s commercial business and pipeline programs, including zuranolone; the anticipated … on advancing one of the industry’s most diversified pipeline in neuroscience that will transform the standard of …
